Glypican‐1 (GPC1), a cell surface proteoglycan, was found to enrich circulating EVs (crEVs) in pancreatic cancer patients, and GPC1‐positve crEVs levels are predictive of disease‐specific survival.95 Here, GPC1 is linked to familial pancreatic carcinoma.